Danaher Co. (NYSE:DHR) Shares Sold by Candriam S.C.A.

Candriam S.C.A. lessened its holdings in Danaher Co. (NYSE:DHR) by 20.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 409,474 shares of the conglomerate’s stock after selling 104,048 shares during the period. Candriam S.C.A.’s holdings in Danaher were worth $102,302,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. North Star Asset Management Inc. raised its stake in shares of Danaher by 1.0% during the 2nd quarter. North Star Asset Management Inc. now owns 104,633 shares of the conglomerate’s stock worth $26,143,000 after buying an additional 1,059 shares during the period. Private Advisor Group LLC raised its position in Danaher by 1.7% during the second quarter. Private Advisor Group LLC now owns 43,200 shares of the conglomerate’s stock worth $10,794,000 after acquiring an additional 733 shares during the period. New York Life Investment Management LLC raised its position in Danaher by 0.8% during the second quarter. New York Life Investment Management LLC now owns 90,790 shares of the conglomerate’s stock worth $22,684,000 after acquiring an additional 682 shares during the period. Addison Advisors LLC grew its position in shares of Danaher by 11.2% in the second quarter. Addison Advisors LLC now owns 667 shares of the conglomerate’s stock valued at $167,000 after purchasing an additional 67 shares during the period. Finally, Palmer Knight Co grew its position in shares of Danaher by 0.4% in the second quarter. Palmer Knight Co now owns 30,645 shares of the conglomerate’s stock valued at $7,657,000 after purchasing an additional 108 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 over the last three months. Insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DHR shares. Barclays raised their price target on shares of Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 24th. Wells Fargo & Company initiated coverage on Danaher in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Leerink Partners raised their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Finally, Stifel Nicolaus upped their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Trading Up 0.6 %

Shares of Danaher stock opened at $266.19 on Friday. The stock has a 50 day moving average of $261.30 and a 200 day moving average of $255.73. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $197.16 billion, a price-to-earnings ratio of 45.12, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company’s revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.05 EPS. As a group, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.